Canada Markets closed

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.17-0.53 (-9.30%)
At close: 04:00PM EST
5.25 +0.08 (+1.55%)
After hours: 06:47PM EST
Currency in USD

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 380.67
52 Week Low 33.59
50-Day Moving Average 38.33
200-Day Moving Average 312.52

Share Statistics

Avg Vol (3 month) 3636.9k
Avg Vol (10 day) 3616.41k
Shares Outstanding 542.68M
Implied Shares Outstanding 6N/A
Float 831.98M
% Held by Insiders 144.99%
% Held by Institutions 18.60%
Shares Short (Aug. 12, 2021) 41.38M
Short Ratio (Aug. 12, 2021) 41.08
Short % of Float (Aug. 12, 2021) 43.85%
Short % of Shares Outstanding (Aug. 12, 2021) 42.67%
Shares Short (prior month Jul. 14, 2021) 41.47M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 4N/A
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:2
Last Split Date 3Mar. 25, 2021

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Jun. 29, 2021


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
Net Income Avi to Common (ttm)-7.88M
Diluted EPS (ttm)N/A
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)50.16M
Total Cash Per Share (mrq)0.97
Total Debt (mrq)3.63M
Total Debt/Equity (mrq)10.33
Current Ratio (mrq)1.51
Book Value Per Share (mrq)-0.11

Cash Flow Statement

Operating Cash Flow (ttm)-8.06M
Levered Free Cash Flow (ttm)N/A